Examples of off-label drug use (OLDU).
\r\n\tMethadone maintenance treatment (MMT) has become the main pharmacological option for the treatment of opioid dependence. Methadone remains the gold standard in the substitution treatment, which is a harm reduction intervention, because the patient does not become abstinent, but there are a series of positive changes. Currently, the surveillance of methadone substitution treatment is considered an ongoing challenge, given the need for the individualization and the increasing of the therapy efficiency. Methadone has been also studied as an analgesic for the management of cancer pain and other chronic pain conditions.
\r\n\r\n\tThe complexity of methadone pharmacology, the high inter-individual variability in methadone pharmacokinetics, the risk of opioid diversion, the overdose and other adverse events pose many challenges to clinicians.
\r\n\tThe aim of the proposed book is to update and summarize the scientific knowledge on the opioid dependence, including the mechanism of opioid dependence, the misuse of prescription opioids and the substitution therapy of opioid dependence.
Despite rapid advancement in science and technology, translating these benefits for care and management of human diseases remains a far slower process than expected. Pharmaceutical industries, research and development (R&D) sectors are facing multifold challenges for taking out any new drug in the market including higher attrition rates, long time span and regulatory restrictions [1]. It takes $2 to $3 billion money and about 13–15 years for developing any new drug in the market with a low success rate of approximately 2% only [2, 3]. Drug development process involves six stages: (i) compound screening and identification of lead compound; (ii) preclinical study; (iii) investigational new drug (IND) application for taking approval to conduct trial in humans, only if preclinical data of the drug is found to be shows effective and safe in animals; (iv) clinical study (phase 1, 2 and 3 clinical trials); (v) new drug application (NDA) if the drug is found to be safe and effective in phase 3 clinical trials; and (vi) post marketing surveillance (PMS) for safety monitoring. However, drug repurposing consists of four stages only: (i) selection of target compound; (ii) clinical trial (phase 2 and 3); (iii) NDA application and (iv) PMS (Figure 1). Thereby’ drug repurposing is a trending way to reduce the effort, cost and time at every step involved in drug development and thus provides an option to bring the new drugs into the market at relatively low investments (Figure 1) [3].
\nPhases in drug development.
‘Drug repurposing’ (or ‘drug repositioning’) is an effective way to find new targets or new indications of any drug that is already FDA approved and existing in the market. It is an excellent alternative over the de novo drug development process which is relatively time consuming and money involved procedure [4]. Since the data including drug efficacy, safety, bioavailability, route and formulation of administration, pharmacokinetic and pharmacodynamic (PK-PD) profile, toxicological data and associated adverse effects, are well known with already approved drugs. Thus, the evaluation process for drug candidates gets facilitated with drug repurposing and drug enters the clinical market for new therapeutic indications. Also, drug repurposing reduces the risk of development failure into the market, thus reducing the cost of the overall drug development process. At present, in the U.S approximately 30% of newly FDA approved drugs are repurposed only [5]. History witnessed numerous drug candidates that have been repurposed either opportunistic or serendipitous. Sildenafil is one of the blockbusters in the history of drug repurposing. Sildenafil, a phosphodiesterase type 5 (PDE5) inhibitor, was introduced in the market in the 1980s by Pfizer for the treatment of coronary artery disease (CAD), hypertension and angina pectoris. During phase-1 trials of sildenafil, it was observed that the patients suffered from marked penile erection. In 1988, the drug was repurposed and approved by FDA for erectile dysfunction in the US market after the drug failed to prove its efficacy in phase-2 trials in angina patients [6]. Another big hit example is thalidomide. In 1957, the drug was developed by German pharmaceutical company named Grünentha for treatment of motion sickness in pregnant women. Soon the drug was withdrawn from the market as its use lead to serious birth defects (malformations of the limbs) and death in approximately 10,000 children in around 46 countries. Subsequently in 2006, the drug was re-approved by FDA for the treatment of multiple myeloma [4]. In the 1960s, amantadine was developed as an antiviral drug to treat influenza infections. After a few years, a patient who was suffering from Parkinson’s disease (PD) had taken amantadine for her flu infection. It was seen that the patient was having improvement in her PD symptoms after taking amantadine. From there, it has been concluded that the drug can be used in treating neurological disorders. Years later, amantadine received FDA approval for treatment of PD [7].
\n“Off-label drug use (OLDU)” defines to prescribe the drug beyond the conditions for which the drug is holding the license for its market authorization. More specifically, off-label means using a drug for indications, dosage form, dose strength, route of administration or in that patient age group which are not approved by FDA [8]. FDA approves a drug to market only if it shows to be effective and safe in preclinical as well as clinical studies, refers to as “on-label drug use”. However, OLDU is being extensively practiced by physicians in situations: first, when two therapeutic conditions possessing same pathophysiology; second, to treat any life-threatening condition where no treatment is available and thereby provide off-label use may be proven helpful to patient; and third, drug has not been studies in specific group or patient age (pediatrics, pregnancy or geriatric). There are many examples of drugs which have been prescribed commonly as “off-label” drugs (Table 1) [9].
\nDrug | \nClass of drug | \nApproved use | \nOff-label use | \n
---|---|---|---|
Desmopressin | \nAntidiuretic hormone | \nCentral diabetes insipidus | \nNocturnal enuresis | \n
Atenolol, propranolol, metoprolol | \nBeta blockers | \nHypertension | \nMigraine prophylaxis | \n
Imipramine, amoxapine | \nTricyclic antidepressant | \nDepression | \nInsomnia, Bulimia, neuropathic pain symptoms | \n
Aspirin | \nNSAIDs | \nAnalgesic | \nAntithrombosis in atrial fibrillation | \n
Indomethacin | \nNSAIDs | \nAnalgesic | \nClosure of patent ductus arteriosus | \n
Erythromycin | \nMacrolide antibiotic | \nHaemophilus and Legionella infection, whooping cough, atypical pneumonia | \nGastroparesis | \n
Examples of off-label drug use (OLDU).
There is no defined definition for orphan diseases (ODs). In the US it is defined as if the disease prevalence affects less than 1 in <200,000, in Japan <50,000 and in Australia <2000. WHO defines the prevalence of less than 6.5–10 in 10,000 [10]. The drug which is used in the treatment of orphan disease is referred to as an orphan drug. For example; haem arginate, is being used to treat porphyria (acute intermittent, variegate and hereditary), ibuprofen to treat patent ductus arteriosus in neonates [11] and N-acetylcysteine for paracetamol poisoning. In orphan diseases (ODs) and their management, the count for orphan diseases exists approximately 6000 but the efforts that are putting off by pharmaceutical and R&D sectors for developing new drugs in their management are negligible cause the huge amount involved in de novo drug development [12]. Only 5% of pharmaceutical industries are taking interest in developing new drugs in orphan disease management [12]. At present, approximately 325 drugs are available in the market, which are being used to treat only 5% of orphan diseases. Drug repurposing provides one of the best faster and economical ways to find new treatment options in ODs (Figure 2). To facilitate drug development and treatment options in orphan disease management FDA Orphan Drug Act (ODA) 1983, has provided many of the benefits or incentives to pharmaceutical and research companies including (i) tax credits (ii) clinical research aids, (iii) fast-track marketing authorization procedures (FDA approval), and (iv) marketing exclusivity [13].
\nResource database for orphan diseases (ODs) and drugs.
In drug repurposing, three major steps are involved which consist of (i) identification of target candidate for new indication (generation of new hypothesis for new indication or new target), (ii) exploration of mechanism or signaling pathway involved in drug or disease and (iii) finally proving the efficacy of drug in phase 2 and 3 clinical trials. Among all steps, identification of lead candidate is one of the most critical steps. This is the step where the most sophisticated and systematic approaches are needed to be implicated for generation of new hypothesis in drug repurposing. Drugs can be repurposed via multiple ways which may be either experimentally, clinical based or computationally (Figure 3). Computational approach is ‘in silico’ based drug repurposing which is further subclassified as either drug-centric or disease-centric. In drug-centric, we find new indications for existing drugs while in disease-centric approach, we try new drugs for an existing disease.
\nApproaches for drug repurposing. (a) Experimental based, (b) clinical based and (c) computational based drug repurposing.
Techniques like chromatography and mass spectrometry are being used to find all possible binding targets of drug candidates. Brehmer et al. conducted a study using HeLa cell extract to identify possible protein targets of gefitinib. The results of mass spectrometry revealed that the drug can interact with 20 different protein kinases which may be treated as possible targets of gefitinib [14].
\nIn the world of drug discovery and development, the term phenotyping screening is used to describe the ways adopted to identify the biological effects of a drug which is either directly or indirectly linked to a disease. With the development of robotic and sensitive screening tools, the approach is used to screen thousands of chemical drug libraries in a single go. It involves the screening of target drug candidates either using cell-based screens (high throughput screening (HTS)) or even whole organism [15]. Cell based assays involve cell lines derived from human or animals, immortalized cell lines or induced pluripotent cells lines (iPSCs), etc. For example, Iljin et al. [16] performed HTS of approximately 5000 small molecules using prostate cancer epithelial cell lines. In this experiment, disulfiram was found to possess selective antineoplastic property which was validated later using genome wide gene expression studies [16]. Important cell-based assays that are being performed in drug discovery and repurposing include: cell viability assay, signaling pathways assay and disease related mechanistic assay. Other cell assays that are being performed routinely in drug development include cell apoptosis, infection, cell motility, cell cycle arrest and many more [17]. Cousin et al. [18] have used zebrafish model to evaluate the efficacy of compounds against tobacco dependence. In this study the authors have found that the agents like apomorphine may be useful in modifying nicotine or ethanol induced dependence behavior [18]. Over the decades in drug discovery, these approaches are getting shifted more toward molecular targets based on phenotypic methods, which rely mainly on molecular targets of drugs and diseases and related mechanisms for hypothesis generation.
\nClinical trials providing positive outcomes are quite rare as most of the drugs fail during Phase II/III trials. But many drugs which already have been marketed during post-marketing surveillance provides different outcome. Some may display different adverse events and some may treat specific kinds of disease with no labeled indication. Many drugs have been repurposed with the help of these trials. Some such examples are apomorphine was indicated for Parkinson’s disease and it was repurposed for erectile dysfunction, drospirenone—oral contraceptive and repurposed for hypertension, dapoxetine—analgesia and depression and repurposed for hypertension [3]. These are very few examples of clinically repurposed drugs, there are many such drugs which have been repurposed with many new indications [1].
\nThis approach is based on already available data such as ligands and receptors. Specific models can be developed in order to locate the targets that have not been discovered/explored yet. These models are developed to discover the novel bio-markers, pathophysiology and receptors for various diseases. This kind of approach could also be beneficial in predicting different adverse reaction related to drugs, their structure activity relationships (SAR), ligands targeting the different pathways, etc., So, this could be mechanism based, pathway-based, receptor-based repositioning of drugs [1].
\nIn-silico screening of various compounds by generating drug library could find a lead molecule resulting targeted therapies. Drug compounds of specific interest from drug libraries can be selected by molecular docking or ligand-based screening which incorporates high-throughput screening (HTS) as large number of compounds are screened in this method [19]. The other methods include standard precision (SP), extra precision (XP).
\nDuring this screening there is no incorporation of information related to any biological or pharmacological as the screening is blinded. Target-based approach links the targets such as any receptor with the pathophysiology behind the disease and therefore the process of drug-discovery revamps. Withstanding to this target-based approach cannot predict the novel/unknown mechanism with the currently available targets of the disease [1].
\nInformation such as protein-protein interaction, cell signaling and metabolic pathways can be useful for predicting the intersection between disease and drugs. The best possible example could be data available from the central database of patients can define the pathways involved in the specific disease are possibly reconstructed for drugs repositioning [19].
\nPredicting the novel mechanism of action by this approach and resulting in drug repurposing for existing drugs. This is possible by gathering information from signaling pathway information, interaction networks of various proteins and also by data obtained from omics. Additionally, this will contribute to precision medicine. As, increasingly the individuals with their respective diseases have different pathophysiology among them. Precision medicine is upcoming solution for all these unique disease specific pathophysiological individuals. Advantages for drug repurposing by these approaches can discover not only different pathophysiological mechanisms but also providing treatment to them with respective drugs [19].
\nMachine learning (ML) techniques such as deep learning (DL), gradient boosted machine with trees (GBM), random forest (RF), support vector machine (SVM), logistic regression with elastic net regularization (EN), deep neural networks (DNN) have been usually applied for repositioning of various drugs [20, 21].
\nThe various interaction patterns such as protein-protein, drug-disease, disease-gene, drug-target, drug-drug, disease-disease and transcriptomes and cell signaling networks are usually procured from different databases, which are interpreted computationally. The network models represent each and everything like drug, disease, gene and related products and their interaction patterns, for example, nodes (drug, disease and genes) and edges (interaction patterns of nodes). Network models are divided in to two types, these includes: network-based cluster approaches and network-based propagation approaches [19].
\nThese kinds of approaches have been proposed in order to determine the mechanism/relationships between the drug and the disease or the drug and the target/receptor. The biological interaction pattern in our human body has a characteristic network. The entities such as disease, drug and the protein share similar kind of interaction pattern in the network-based cluster approaches. This approach has been incorporated to develop various kinds of modules using the network topology-based cluster algorithms such as cliques/clusters/groups, subnetworks. They portray relationships or pattern of interaction between drug-drug, disease, target/receptors. The overlapping clusters cannot be detected by CLIQUE, OPTICS, DBSCAN and STING [20]. These modules are most commonly used network-based cluster approaches. Examples of repurposed drugs using network approach are atomoxetine indicated for Parkinson’s disease and repurposed for attention deficit hyperactivity disorder (ADHD), etanercept indicated for rheumatoid arthritis and repurposed for asthma [3].
\nThese approaches have been categorized as another important approach under network strategies. They can be classified in two types: local and global approach. The information under this approach circulates from node (source) to all the nodes which are networked to each other and followed by subnetwork nodes [19].
\nMany studies have stated that these techniques are really being helpful and providing some useful results in obtaining interaction patterns/relationships between the drug—target/receptor, gene, disease. Local propagation procures small/fewer amount of data from the database and displays improper results. In opposing to this global approach gathers all of the data from database/network and make correct predictions. Currently, researchers are working on global approach for drug repurposing/repositioning [1, 19].
\nGenome-wide association studies (GWAS) has been widely used to determine the genetic alterations in whole genome which contribute to specific diseases and provides the pathophysiology of various diseases. The data obtained from the GWAS helps to identify novel targets which contributes to the specific diseases can provide repositioning of several drugs. Human Genome Project has already been completed and vast amount of data is available for specific diseases. So, there is a huge opportunity for various drugs that could be repositioned and provide beneficial outcome. However, the data available from GWAS does not provide exact pathophysiological mechanism and the available data is not appropriate due to the gene variant. As, there many still thousands of genes hidden which is yet to be discovered and these hidden genes may be contributing largely behind pathophysiology of various diseases [1].
\nSignature inversion method is defined as the approaches which screens the inverse relationships/interaction pattern of drug and the disease by correlating the gene expression information between the drug-disease. As defined this method utilizes the expression of genes to discover off-target mechanisms as well as novel pathophysiological mechanisms related to diseases. One of the prime advantages of these approaches is that they identify unique/novel mechanisms of action for drugs. Additionally, unlike knowledge-based methods that use the databases to predict the mechanism or action of drugs, more molecular- and/or genetic-level mechanisms are involved in signature-based repurposing methods [1].
\nThe data available in the literature contains large and varied amount of information/data for all the drugs in the database as well as for the diseases (including orphan/rare diseases) which are commonly occurred in individuals. Through these data one can potentially predict the new indications of existing drugs via text mining approach. Gene ontology/biological ontology allows us to correlate the available information and analyze all the biological data from different databases. One such example of repurposed drug is Everolimus indicated for immunosuppressant and repurposed for pancreatic neuroendocrine tumors [3].
\nSemantic inference incorporates techniques like topic modeling which utilizes different databases for the discovery of repurposing of existing drugs. Example of repurposed drug was amphetamine which was indicated for CNS stimulant and repurposed for hyperkinesis in children (ADHD) [3].
\nApproximately 7000 rare diseases are currently present in the world and more than 95% among these lack therapeutic agents approved by US-FDA [1]. The concept behind orphan disease might be many yet they have a single key point which is common that is the disease affects a minor part of the population. The definition of orphan diseases differs in different countries. In US, orphan disease is the one affecting fewer than 2 lakh people, in Japan the disease should affect fewer than 50,000 people to be called as orphan disease and in Europe the prevalence should be 5 in 10,000 [1, 22].
\nIt is very challenging to develop new drugs for the treatment of rare diseases because the number of patients suffering from these diseases are very limited and are distributed over a vast geographical area. Another issue is of high variability among these diseases, influenced mostly by genetic factors. Financially, the development and subsequent production of these drugs is not viable for the pharmaceutical companies therefore drug repurposing for orphan diseases is a good option [22]. The patients requiring immediate treatment also do not have the luxury of more time at their disposal therefore a new strategy is needed so that the drugs are made available faster and cheaper to these patients. The pathology and various biochemical pathways of many orphan diseases are not very well known. Computational techniques will be a helpful option in the case where the underlying mechanism of the disease is not well understood. The advancement of the huge scale genomic sequencing project may lead to the understanding of the genetic variations that may be the cause of these diseases and it may lead to possibility of repurposing the drugs which are targeting the concerned protein [1]. There are few examples of repurposed drugs described in Table 2.
\nDrug | \nOriginal indication | \nNew indication | \n
---|---|---|
Thalidomide | \nMorning sickness | \nErythema nodosum leprosum and multiple myeloma | \n
Sildenafil | \nAngina | \nErectile dysfunction | \n
Minoxidil | \nHypertension | \nHair loss | \n
Zidovudine | \nCancer | \nHIV/AIDS | \n
Celecoxib | \nPain and inflammation | \nFamilial adenomatous polyps | \n
Atomoxetine | \nParkinson disease | \nADHD | \n
Aspirin | \nAnalgesia | \nColorectal cancer | \n
Ketoconazole | \nFungal infections | \nCushing syndrome | \n
Topiramate | \nEpilepsy | \nObesity | \n
Dapoxetine | \nAnalgesia and depression | \nPremature ejaculation | \n
Raloxifene | \nOsteoporosis | \nBreast cancer | \n
Rituximab | \nCancers | \nRheumatoid arthritis | \n
Duloxetine | \nDepression | \nStress urinary incontinence. | \n
Fingolimod | \nTransplant rejection | \nMultiple sclerosis | \n
Bupropion | \nDepression | \nSmoking cessation | \n
Lidocaine | \nLocal anesthetic | \nArrhythmia | \n
A few examples of repurposed drugs with their new indication.
The approved drugs have already undergone intense testing like the safety studies, bioavailability studies and PK/PD studies and therefore drug repurposing leads to significant cost cutting and faster development [22]. Hence, this is an attractive prospect for the pharmaceutical industry as well. A total of 51 new medications reaching the market in 2009, the drugs which came to the market via the strategy of drug repurposing were 30% [23].
\nThere are particular regulations designed to promote the research into orphan diseases and these rules could give market exclusiveness in circumstances repurposed agents cannot be protected by the patent. The Orphan Drug Act (ODA; 1983) was introduced for the first time which reflected the issues regarding the economics of drug development for orphan disease and how it was unfavorable. FDA has licensed about 360 agents for rare diseases since 1983 as compared to less than 50 agents before 1983 [24]. US legislation provides for faster FDA approval, tax incentives and funding support for research in orphan diseases. Market protection is also one of the incentives in which a generic form is not allowed to come to the market for 7 years. Tax concession, waiving of the regulatory fees are also the incentives which are provided. Similar legislation has been implemented in Singapore, Japan, Europe and Australia after the success of ODA, with each jurisdiction having a little bit of difference in the definition of the indication and the incentives to be provided [1].
\nAnother area of concern is the broad group of infectious diseases known to affect more than 1 billion population in tropical and subtropical areas [22]. Populations that are severely impacted are the people living below poverty line, not having appropriate sanitary conditions and in direct contact with contagious vectors or domestic animals [25]. The therapies currently present have many drawbacks like pricing and increase probability of drug resistance. Moreover, there are not much financial gains for investing money in developing drugs for these diseases as the patient population is unable to afford them [26]. Subsequently, given that the profit-making companies produce almost all the drugs, these firms will hardly be having any interest in investing in drug research and development which will not produce high financial returns. For this reason, development of therapies for these diseases becomes increasingly necessary. As discussed earlier that drug repurposing is an effective method due to various reasons, it can also be effectively used in this area where resources are limited and there is a huge need for productive therapies. Miltefosine, used for visceral leishmaniasis originally was antineoplastic agent whereas Amphotericin B used to treat fungal infections was repurposed for treating visceral leishmaniasis [22]. Other examples include Tamoxifen (agent for breast cancer) has shown to have anti-leishmanial activity, eflornithine (topical agent for hirsutism) has shown to be effective for sleeping sickness and auranofin (drug for rheumatoid arthritis) has shown to be effective against lymphatic filariasis and Onchocerca volvulus induced river blindness [27].
\nThese days, multiple researches have demonstrated encouraging results in terms of repositioning supported by computational methods like chemical genomics screening for developing agents for such kind of diseases like schistosomiasis [28]. Some other examples where drug repurposing has shown promise for these diseases are vandetanib, trametinib and atorvastatin [29, 30].
\nDrug repurposing strategies have also been used in the cases of viral diseases like Zika virus where FDA approved drug for hepatitis C which is Sofosbuvir has shown promising results [22]. The target of this drug is RNA polymerase which is present in Hepatitis C and Zika virus and has shown to reduce viral load in experimental studies [31, 32]. The same is the case with prochlorperazine by targeting the binding and the entry of the virus to host cells has shown to have a strong antiviral activity against dengue virus [22].
\nDrug repurposing is cheaper and faster than the conventional methods and thus gives hope to the patients where the population suffering from the disease is much smaller and making the traditional model of drug discovery nonviable. A collective effort is required among all the stakeholders if already available drugs have to be repurposed. This approach helps in reducing the potential risks and the expense of developing a new agent, therefore having the ability of revolutionizing the drug market of orphan diseases.
\nIn the US, to get permission for drug repurposing, research and pharma companies need to file applications under suitable sections including 505(b)(1), or 505(b)(2) or 505(j), depending upon the regulatory paths. Further, the company needs to fill NDA type 6 and sNDA (supplemental new drug application) for new indication of drug, NDA type 3 for new dosage form and NDA type 4 for drug new combination in drug repurposing [1, 33].
\nAs orphan disease affects a small percentage of the population, research and pharma companies face great challenge and burden in developing drugs for its management because of small market potential. Patients fail to get proper care, diagnosis and treatment. Even if the treatment is available, it is relatively expensive. Thus, drug repurposing can be of great help in orphan disease therapeutics. It saves both’ the time and money involved in the drug development process. In October 2010, “Dr Ruxandra Draghia-Akli, the Directorate-General for Research and Innovation (DG RTD) of the European Commission (EC) and Dr Francis Collins, US National Institutes of Health (NIH)” at Reykjavík (Iceland), launched the International Rare Diseases Research Consortium (IRDiRC) to look after the drug and research development in orphan/rare diseases [34]. This consortium unites both government and private research funding societies to advance the drug development for orphan diseases at global level including task forces and drug repurposing in orphan disease therapeutics.
\nThe research in rare diseases has already changed the global approach because earlier researchers were not much interested in repurposing the existing drug but some global breakthrough has really changed the minds of pharma companies and examples are alglucerase that was obtained from human placental tissue and was widely used for Type I Gaucher disease as a “first enzyme replacement therapy” and, it was also approved by FDA in 1991. However, it was withdrawn from the market due to adverse effect and already available drugs in the market which are prepared from recombinant DNA technology which are safe to use [35]. Fomivirsen which is an antisense oligonucleotide and was approved by FDA for Cytomegalovirus in 1998 but it has been withdrawn from the market due to the development of highly active antiretroviral therapy (HAART) but this was the “first antisense oligonucleotide therapy” [35]. Imatinib was approved by FDA in 2001 for Philadelphia chromosome-positive chronic myelogenous leukemia (CML) as “first targeted cancer therapy” [35]. Alipogene tiparvovec was the “first targeted gene therapy” to be approved in Europe in 2012 for reversing lipoprotein lipase deficiency (LPLD) in patients with pancreatitis [35]. Strimvelis was the “First ex-vivo gene therapy” approved for patients with Severe Combined Immunodeficiency due to Adenosine Deaminase deficiency (ADA-SCID) [35]. USFDA has approved Holoclar as orphan drug for the treatment of limbal stem cell deficiency (LSCD). Currently, this drug is in Phase IV trial and completing in mid of the year 2020 [36].
\nTo overcome R&D-associated financial challenges and clinical trials-related failures of novel drugs, at present scenario, pharmaceutical companies are much more interested in switching to “drug repurposing” or “drug repositioning” drug development by adopting various computational approaches rather than going for de novo drug discovery, which is relatively expensive, risky and time consuming [37]. According to Southall et al. [35], the global market for drug repositioning will possibly be hiked to over $31 billion by 2020, up from about $24 billion in 2015, thus representing large commercial possibility [35].
\n\nDe novo drug development is being time consuming, costly and risk-prone venture ‘drug repurposing’ has drawn attention of all pharma companies and R and D sectors which offers faster and cheaper ways for bringing new drugs into the market especially for targeting ODs. Based upon the benefits provided by drug repurposing, the development of more sophisticated and systematic approach is required to find more drug candidates that can be fitted into the picture of promising targets for repurposing.
\nThere are no conflicts of interests.
None.
\nWe pride ourselves on our belief that scientific progress is generated by collaboration, that the playing field for scientific research should be leveled globally, and that research conducted in a democratic environment, with the use of innovative technologies, should be made available to anyone.
\n\nWe look forward to hearing from individuals and organizations who are interested in new discoveries and sharing their research.
",metaTitle:"Contact us",metaDescription:null,metaKeywords:null,canonicalURL:"/page/contact-us",contentRaw:'[{"type":"htmlEditorComponent","content":"Headquarters
\\n\\n\\n\\n
London
\\n\\nIntechOpen Limited
\\n\\n5 Princes Gate Court,
\\n\\nLondon, SW7 2QJ, UK
\\n\\nPhone: +44 20 8089 5702
\\n\\n\\n\\n
Rijeka
\\n\\nIN TECH d.o.o.
\\n\\nJaneza Trdine 9
\\n\\n51000 Rijeka - Croatia
\\n\\nPhone: +385 (0) 51 686 165
\\n"},{"imagePath":"/media/thumbnail/780x430/3","type":"mediaComponent","mediaType":"image","mimeType":"image/jpeg","caption":"","originalUrl":"/media/thumbnail/600x600/3","alignment":"center"},{"type":"htmlEditorComponent","content":"General Inquires: info@intechopen.com
\\n\\nFunders: funders@intechopen.com
\\n\\n*INTECHOPEN LIMITED is a privately owned company registered in England and Wales, No. 11086078 Registered Office: 5 Princes Gate Court, London, SW7 2QJ, UK
\\n\\n\\n"}]'},components:[{type:"htmlEditorComponent",content:"
Headquarters
\n\n\n\n
London
\n\nIntechOpen Limited
\n\n5 Princes Gate Court,
\n\nLondon, SW7 2QJ, UK
\n\nPhone: +44 20 8089 5702
\n\n\n\n
Rijeka
\n\nIN TECH d.o.o.
\n\nJaneza Trdine 9
\n\n51000 Rijeka - Croatia
\n\nPhone: +385 (0) 51 686 165
\n"},{imagePath:"/media/thumbnail/780x430/3",type:"mediaComponent",mediaType:"image",mimeType:"image/jpeg",caption:"",originalUrl:"/media/thumbnail/600x600/3",alignment:"center"},{type:"htmlEditorComponent",content:'General Inquires: info@intechopen.com
\n\nFunders: funders@intechopen.com
\n\n*INTECHOPEN LIMITED is a privately owned company registered in England and Wales, No. 11086078 Registered Office: 5 Princes Gate Court, London, SW7 2QJ, UK
\n\n\n'}]},successStories:{items:[]},authorsAndEditors:{filterParams:{sort:"featured,name"},profiles:[{id:"6700",title:"Dr.",name:"Abbass A.",middleName:null,surname:"Hashim",slug:"abbass-a.-hashim",fullName:"Abbass A. Hashim",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/6700/images/1864_n.jpg",biography:"Currently I am carrying out research in several areas of interest, mainly covering work on chemical and bio-sensors, semiconductor thin film device fabrication and characterisation.\nAt the moment I have very strong interest in radiation environmental pollution and bacteriology treatment. The teams of researchers are working very hard to bring novel results in this field. I am also a member of the team in charge for the supervision of Ph.D. students in the fields of development of silicon based planar waveguide sensor devices, study of inelastic electron tunnelling in planar tunnelling nanostructures for sensing applications and development of organotellurium(IV) compounds for semiconductor applications. I am a specialist in data analysis techniques and nanosurface structure. I have served as the editor for many books, been a member of the editorial board in science journals, have published many papers and hold many patents.",institutionString:null,institution:{name:"Sheffield Hallam University",country:{name:"United Kingdom"}}},{id:"54525",title:"Prof.",name:"Abdul Latif",middleName:null,surname:"Ahmad",slug:"abdul-latif-ahmad",fullName:"Abdul Latif Ahmad",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"20567",title:"Prof.",name:"Ado",middleName:null,surname:"Jorio",slug:"ado-jorio",fullName:"Ado Jorio",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Universidade Federal de Minas Gerais",country:{name:"Brazil"}}},{id:"47940",title:"Dr.",name:"Alberto",middleName:null,surname:"Mantovani",slug:"alberto-mantovani",fullName:"Alberto Mantovani",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"12392",title:"Mr.",name:"Alex",middleName:null,surname:"Lazinica",slug:"alex-lazinica",fullName:"Alex Lazinica",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/12392/images/7282_n.png",biography:"Alex Lazinica is the founder and CEO of IntechOpen. After obtaining a Master's degree in Mechanical Engineering, he continued his PhD studies in Robotics at the Vienna University of Technology. Here he worked as a robotic researcher with the university's Intelligent Manufacturing Systems Group as well as a guest researcher at various European universities, including the Swiss Federal Institute of Technology Lausanne (EPFL). During this time he published more than 20 scientific papers, gave presentations, served as a reviewer for major robotic journals and conferences and most importantly he co-founded and built the International Journal of Advanced Robotic Systems- world's first Open Access journal in the field of robotics. Starting this journal was a pivotal point in his career, since it was a pathway to founding IntechOpen - Open Access publisher focused on addressing academic researchers needs. Alex is a personification of IntechOpen key values being trusted, open and entrepreneurial. Today his focus is on defining the growth and development strategy for the company.",institutionString:null,institution:{name:"TU Wien",country:{name:"Austria"}}},{id:"19816",title:"Prof.",name:"Alexander",middleName:null,surname:"Kokorin",slug:"alexander-kokorin",fullName:"Alexander Kokorin",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/19816/images/1607_n.jpg",biography:"Alexander I. Kokorin: born: 1947, Moscow; DSc., PhD; Principal Research Fellow (Research Professor) of Department of Kinetics and Catalysis, N. Semenov Institute of Chemical Physics, Russian Academy of Sciences, Moscow.\r\nArea of research interests: physical chemistry of complex-organized molecular and nanosized systems, including polymer-metal complexes; the surface of doped oxide semiconductors. He is an expert in structural, absorptive, catalytic and photocatalytic properties, in structural organization and dynamic features of ionic liquids, in magnetic interactions between paramagnetic centers. The author or co-author of 3 books, over 200 articles and reviews in scientific journals and books. He is an actual member of the International EPR/ESR Society, European Society on Quantum Solar Energy Conversion, Moscow House of Scientists, of the Board of Moscow Physical Society.",institutionString:null,institution:{name:"Semenov Institute of Chemical Physics",country:{name:"Russia"}}},{id:"62389",title:"PhD.",name:"Ali Demir",middleName:null,surname:"Sezer",slug:"ali-demir-sezer",fullName:"Ali Demir Sezer",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/62389/images/3413_n.jpg",biography:"Dr. Ali Demir Sezer has a Ph.D. from Pharmaceutical Biotechnology at the Faculty of Pharmacy, University of Marmara (Turkey). He is the member of many Pharmaceutical Associations and acts as a reviewer of scientific journals and European projects under different research areas such as: drug delivery systems, nanotechnology and pharmaceutical biotechnology. Dr. Sezer is the author of many scientific publications in peer-reviewed journals and poster communications. Focus of his research activity is drug delivery, physico-chemical characterization and biological evaluation of biopolymers micro and nanoparticles as modified drug delivery system, and colloidal drug carriers (liposomes, nanoparticles etc.).",institutionString:null,institution:{name:"Marmara University",country:{name:"Turkey"}}},{id:"61051",title:"Prof.",name:"Andrea",middleName:null,surname:"Natale",slug:"andrea-natale",fullName:"Andrea Natale",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"100762",title:"Prof.",name:"Andrea",middleName:null,surname:"Natale",slug:"andrea-natale",fullName:"Andrea Natale",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"St David's Medical Center",country:{name:"United States of America"}}},{id:"107416",title:"Dr.",name:"Andrea",middleName:null,surname:"Natale",slug:"andrea-natale",fullName:"Andrea Natale",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Texas Cardiac Arrhythmia",country:{name:"United States of America"}}},{id:"64434",title:"Dr.",name:"Angkoon",middleName:null,surname:"Phinyomark",slug:"angkoon-phinyomark",fullName:"Angkoon Phinyomark",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/64434/images/2619_n.jpg",biography:"My name is Angkoon Phinyomark. I received a B.Eng. degree in Computer Engineering with First Class Honors in 2008 from Prince of Songkla University, Songkhla, Thailand, where I received a Ph.D. degree in Electrical Engineering. My research interests are primarily in the area of biomedical signal processing and classification notably EMG (electromyography signal), EOG (electrooculography signal), and EEG (electroencephalography signal), image analysis notably breast cancer analysis and optical coherence tomography, and rehabilitation engineering. I became a student member of IEEE in 2008. During October 2011-March 2012, I had worked at School of Computer Science and Electronic Engineering, University of Essex, Colchester, Essex, United Kingdom. In addition, during a B.Eng. I had been a visiting research student at Faculty of Computer Science, University of Murcia, Murcia, Spain for three months.\n\nI have published over 40 papers during 5 years in refereed journals, books, and conference proceedings in the areas of electro-physiological signals processing and classification, notably EMG and EOG signals, fractal analysis, wavelet analysis, texture analysis, feature extraction and machine learning algorithms, and assistive and rehabilitative devices. I have several computer programming language certificates, i.e. Sun Certified Programmer for the Java 2 Platform 1.4 (SCJP), Microsoft Certified Professional Developer, Web Developer (MCPD), Microsoft Certified Technology Specialist, .NET Framework 2.0 Web (MCTS). I am a Reviewer for several refereed journals and international conferences, such as IEEE Transactions on Biomedical Engineering, IEEE Transactions on Industrial Electronics, Optic Letters, Measurement Science Review, and also a member of the International Advisory Committee for 2012 IEEE Business Engineering and Industrial Applications and 2012 IEEE Symposium on Business, Engineering and Industrial Applications.",institutionString:null,institution:{name:"Joseph Fourier University",country:{name:"France"}}},{id:"55578",title:"Dr.",name:"Antonio",middleName:null,surname:"Jurado-Navas",slug:"antonio-jurado-navas",fullName:"Antonio Jurado-Navas",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/55578/images/4574_n.png",biography:"Antonio Jurado-Navas received the M.S. degree (2002) and the Ph.D. degree (2009) in Telecommunication Engineering, both from the University of Málaga (Spain). He first worked as a consultant at Vodafone-Spain. From 2004 to 2011, he was a Research Assistant with the Communications Engineering Department at the University of Málaga. In 2011, he became an Assistant Professor in the same department. From 2012 to 2015, he was with Ericsson Spain, where he was working on geo-location\ntools for third generation mobile networks. Since 2015, he is a Marie-Curie fellow at the Denmark Technical University. His current research interests include the areas of mobile communication systems and channel modeling in addition to atmospheric optical communications, adaptive optics and statistics",institutionString:null,institution:{name:"University of Malaga",country:{name:"Spain"}}}],filtersByRegion:[{group:"region",caption:"North America",value:1,count:5766},{group:"region",caption:"Middle and South America",value:2,count:5227},{group:"region",caption:"Africa",value:3,count:1717},{group:"region",caption:"Asia",value:4,count:10366},{group:"region",caption:"Australia and Oceania",value:5,count:897},{group:"region",caption:"Europe",value:6,count:15789}],offset:12,limit:12,total:118187},chapterEmbeded:{data:{}},editorApplication:{success:null,errors:{}},ofsBooks:{filterParams:{topicId:"12"},books:[{type:"book",id:"10760",title:"Steppe Biome",subtitle:null,isOpenForSubmission:!0,hash:"982f06cee6ee2f27339f3c263b3e6560",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/10760.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10763",title:"Biodiversity of Ecosystems",subtitle:null,isOpenForSubmission:!0,hash:"c96b42d4539957c58dfc2eb8fd9ffc21",slug:null,bookSignature:"Dr. Levente Hufnagel",coverURL:"https://cdn.intechopen.com/books/images_new/10763.jpg",editedByType:null,editors:[{id:"10864",title:"Dr.",name:"Levente",surname:"Hufnagel",slug:"levente-hufnagel",fullName:"Levente Hufnagel"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10765",title:"Environmental Management",subtitle:null,isOpenForSubmission:!0,hash:"e5ba02fedd7c87f0ab66414f3b07de0c",slug:null,bookSignature:"Dr. John P. Tiefenbacher",coverURL:"https://cdn.intechopen.com/books/images_new/10765.jpg",editedByType:null,editors:[{id:"73876",title:"Dr.",name:"John P.",surname:"Tiefenbacher",slug:"john-p.-tiefenbacher",fullName:"John P. Tiefenbacher"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10766",title:"Landscape Architecture",subtitle:null,isOpenForSubmission:!0,hash:"a0a54a9ab661e4765fee76ce580cd121",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/10766.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10845",title:"Marine Ecosystems",subtitle:null,isOpenForSubmission:!0,hash:"b369ac809068d2ebf1f8c26418cc6bec",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/10845.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10846",title:"Stormwater",subtitle:null,isOpenForSubmission:!0,hash:"9bfae8caba192ce3ab6744c9cbefa210",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/10846.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10178",title:"Environmental Emissions",subtitle:null,isOpenForSubmission:!0,hash:"febf21ec717bfe20ae25a9dab9b5d438",slug:"environmental-emissions",bookSignature:"Richard Viskup",coverURL:"https://cdn.intechopen.com/books/images_new/10178.jpg",editedByType:"Edited by",editors:[{id:"103742",title:"Dr.",name:"Richard",surname:"Viskup",slug:"richard-viskup",fullName:"Richard Viskup"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}],filtersByTopic:[{group:"topic",caption:"Agricultural and Biological Sciences",value:5,count:15},{group:"topic",caption:"Biochemistry, Genetics and Molecular Biology",value:6,count:3},{group:"topic",caption:"Business, Management and Economics",value:7,count:1},{group:"topic",caption:"Chemistry",value:8,count:7},{group:"topic",caption:"Computer and Information Science",value:9,count:6},{group:"topic",caption:"Earth and Planetary Sciences",value:10,count:7},{group:"topic",caption:"Engineering",value:11,count:15},{group:"topic",caption:"Environmental Sciences",value:12,count:2},{group:"topic",caption:"Immunology and Microbiology",value:13,count:3},{group:"topic",caption:"Materials Science",value:14,count:5},{group:"topic",caption:"Mathematics",value:15,count:1},{group:"topic",caption:"Medicine",value:16,count:26},{group:"topic",caption:"Neuroscience",value:18,count:1},{group:"topic",caption:"Pharmacology, Toxicology and Pharmaceutical Science",value:19,count:2},{group:"topic",caption:"Physics",value:20,count:2},{group:"topic",caption:"Psychology",value:21,count:4},{group:"topic",caption:"Social Sciences",value:23,count:2},{group:"topic",caption:"Technology",value:24,count:1},{group:"topic",caption:"Veterinary Medicine and Science",value:25,count:1},{group:"topic",caption:"Environmental Pollution",value:133,count:1},{group:"topic",caption:"Dynamical Systems Theory",value:966,count:1}],offset:12,limit:12,total:7},popularBooks:{featuredBooks:[{type:"book",id:"9385",title:"Renewable Energy",subtitle:"Technologies and Applications",isOpenForSubmission:!1,hash:"a6b446d19166f17f313008e6c056f3d8",slug:"renewable-energy-technologies-and-applications",bookSignature:"Tolga Taner, Archana Tiwari and Taha Selim Ustun",coverURL:"https://cdn.intechopen.com/books/images_new/9385.jpg",editors:[{id:"197240",title:"Associate Prof.",name:"Tolga",middleName:null,surname:"Taner",slug:"tolga-taner",fullName:"Tolga Taner"}],equalEditorOne:{id:"186791",title:"Dr.",name:"Archana",middleName:null,surname:"Tiwari",slug:"archana-tiwari",fullName:"Archana Tiwari",profilePictureURL:"https://mts.intechopen.com/storage/users/186791/images/system/186791.jpg",biography:"Dr. Archana Tiwari is Associate Professor at Amity University, India. Her research interests include renewable sources of energy from microalgae and further utilizing the residual biomass for the generation of value-added products, bioremediation through microalgae and microbial consortium, antioxidative enzymes and stress, and nutraceuticals from microalgae. She has been working on algal biotechnology for the last two decades. She has published her research in many international journals and has authored many books and chapters with renowned publishing houses. She has also delivered talks as an invited speaker at many national and international conferences. Dr. Tiwari is the recipient of several awards including Researcher of the Year and Distinguished Scientist.",institutionString:"Amity University",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"3",totalChapterViews:"0",totalEditedBooks:"1",institution:{name:"Amity University",institutionURL:null,country:{name:"India"}}},equalEditorTwo:{id:"197609",title:"Prof.",name:"Taha Selim",middleName:null,surname:"Ustun",slug:"taha-selim-ustun",fullName:"Taha Selim Ustun",profilePictureURL:"https://mts.intechopen.com/storage/users/197609/images/system/197609.jpeg",biography:"Dr. Taha Selim Ustun received a Ph.D. in Electrical Engineering from Victoria University, Melbourne, Australia. He is a researcher with the Fukushima Renewable Energy Institute, AIST (FREA), where he leads the Smart Grid Cybersecurity Laboratory. Prior to that, he was a faculty member with the School of Electrical and Computer Engineering, Carnegie Mellon University, Pittsburgh, PA, USA. His current research interests include power systems protection, communication in power networks, distributed generation, microgrids, electric vehicle integration, and cybersecurity in smart grids. He serves on the editorial boards of IEEE Access, IEEE Transactions on Industrial Informatics, Energies, Electronics, Electricity, World Electric Vehicle and Information journals. Dr. Ustun is a member of the IEEE 2004 and 2800, IEC Renewable Energy Management WG 8, and IEC TC 57 WG17. He has been invited to run specialist courses in Africa, India, and China. He has delivered talks for the Qatar Foundation, the World Energy Council, the Waterloo Global Science Initiative, and the European Union Energy Initiative (EUEI). His research has attracted funding from prestigious programs in Japan, Australia, the European Union, and North America.",institutionString:"Fukushima Renewable Energy Institute, AIST (FREA)",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"1",totalChapterViews:"0",totalEditedBooks:"0",institution:{name:"National Institute of Advanced Industrial Science and Technology",institutionURL:null,country:{name:"Japan"}}},equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"8985",title:"Natural Resources Management and Biological Sciences",subtitle:null,isOpenForSubmission:!1,hash:"5c2e219a6c021a40b5a20c041dea88c4",slug:"natural-resources-management-and-biological-sciences",bookSignature:"Edward R. Rhodes and Humood Naser",coverURL:"https://cdn.intechopen.com/books/images_new/8985.jpg",editors:[{id:"280886",title:"Prof.",name:"Edward R",middleName:null,surname:"Rhodes",slug:"edward-r-rhodes",fullName:"Edward R Rhodes"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9027",title:"Human Blood Group Systems and Haemoglobinopathies",subtitle:null,isOpenForSubmission:!1,hash:"d00d8e40b11cfb2547d1122866531c7e",slug:"human-blood-group-systems-and-haemoglobinopathies",bookSignature:"Osaro Erhabor and Anjana Munshi",coverURL:"https://cdn.intechopen.com/books/images_new/9027.jpg",editors:[{id:"35140",title:null,name:"Osaro",middleName:null,surname:"Erhabor",slug:"osaro-erhabor",fullName:"Osaro Erhabor"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"7841",title:"New Insights Into Metabolic Syndrome",subtitle:null,isOpenForSubmission:!1,hash:"ef5accfac9772b9e2c9eff884f085510",slug:"new-insights-into-metabolic-syndrome",bookSignature:"Akikazu Takada",coverURL:"https://cdn.intechopen.com/books/images_new/7841.jpg",editors:[{id:"248459",title:"Dr.",name:"Akikazu",middleName:null,surname:"Takada",slug:"akikazu-takada",fullName:"Akikazu Takada"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"8558",title:"Aerodynamics",subtitle:null,isOpenForSubmission:!1,hash:"db7263fc198dfb539073ba0260a7f1aa",slug:"aerodynamics",bookSignature:"Mofid Gorji-Bandpy and Aly-Mousaad Aly",coverURL:"https://cdn.intechopen.com/books/images_new/8558.jpg",editors:[{id:"35542",title:"Prof.",name:"Mofid",middleName:null,surname:"Gorji-Bandpy",slug:"mofid-gorji-bandpy",fullName:"Mofid Gorji-Bandpy"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9668",title:"Chemistry and Biochemistry of Winemaking, Wine Stabilization and Aging",subtitle:null,isOpenForSubmission:!1,hash:"c5484276a314628acf21ec1bdc3a86b9",slug:"chemistry-and-biochemistry-of-winemaking-wine-stabilization-and-aging",bookSignature:"Fernanda Cosme, Fernando M. Nunes and Luís Filipe-Ribeiro",coverURL:"https://cdn.intechopen.com/books/images_new/9668.jpg",editors:[{id:"186819",title:"Prof.",name:"Fernanda",middleName:null,surname:"Cosme",slug:"fernanda-cosme",fullName:"Fernanda Cosme"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"7847",title:"Medical Toxicology",subtitle:null,isOpenForSubmission:!1,hash:"db9b65bea093de17a0855a1b27046247",slug:"medical-toxicology",bookSignature:"Pınar Erkekoglu and Tomohisa Ogawa",coverURL:"https://cdn.intechopen.com/books/images_new/7847.jpg",editors:[{id:"109978",title:"Prof.",name:"Pınar",middleName:null,surname:"Erkekoglu",slug:"pinar-erkekoglu",fullName:"Pınar Erkekoglu"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"8620",title:"Mining Techniques",subtitle:"Past, Present and Future",isOpenForSubmission:!1,hash:"b65658f81d14e9e57e49377869d3a575",slug:"mining-techniques-past-present-and-future",bookSignature:"Abhay Soni",coverURL:"https://cdn.intechopen.com/books/images_new/8620.jpg",editors:[{id:"271093",title:"Dr.",name:"Abhay",middleName:null,surname:"Soni",slug:"abhay-soni",fullName:"Abhay Soni"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9660",title:"Inland Waters",subtitle:"Dynamics and Ecology",isOpenForSubmission:!1,hash:"975c26819ceb11a926793bc2adc62bd6",slug:"inland-waters-dynamics-and-ecology",bookSignature:"Adam Devlin, Jiayi Pan and Mohammad Manjur Shah",coverURL:"https://cdn.intechopen.com/books/images_new/9660.jpg",editors:[{id:"280757",title:"Dr.",name:"Adam",middleName:"Thomas",surname:"Devlin",slug:"adam-devlin",fullName:"Adam Devlin"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9122",title:"Cosmetic Surgery",subtitle:null,isOpenForSubmission:!1,hash:"207026ca4a4125e17038e770d00ee152",slug:"cosmetic-surgery",bookSignature:"Yueh-Bih Tang",coverURL:"https://cdn.intechopen.com/books/images_new/9122.jpg",editors:[{id:"202122",title:"Prof.",name:"Yueh-Bih",middleName:null,surname:"Tang",slug:"yueh-bih-tang",fullName:"Yueh-Bih Tang"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9043",title:"Parenting",subtitle:"Studies by an Ecocultural and Transactional Perspective",isOpenForSubmission:!1,hash:"6d21066c7438e459e4c6fb13217a5c8c",slug:"parenting-studies-by-an-ecocultural-and-transactional-perspective",bookSignature:"Loredana Benedetto and Massimo Ingrassia",coverURL:"https://cdn.intechopen.com/books/images_new/9043.jpg",editors:[{id:"193200",title:"Prof.",name:"Loredana",middleName:null,surname:"Benedetto",slug:"loredana-benedetto",fullName:"Loredana Benedetto"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9731",title:"Oxidoreductase",subtitle:null,isOpenForSubmission:!1,hash:"852e6f862c85fc3adecdbaf822e64e6e",slug:"oxidoreductase",bookSignature:"Mahmoud Ahmed Mansour",coverURL:"https://cdn.intechopen.com/books/images_new/9731.jpg",editors:[{id:"224662",title:"Prof.",name:"Mahmoud Ahmed",middleName:null,surname:"Mansour",slug:"mahmoud-ahmed-mansour",fullName:"Mahmoud Ahmed Mansour"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}}],offset:12,limit:12,total:5227},hotBookTopics:{hotBooks:[],offset:0,limit:12,total:null},publish:{},publishingProposal:{success:null,errors:{}},books:{featuredBooks:[{type:"book",id:"9385",title:"Renewable Energy",subtitle:"Technologies and Applications",isOpenForSubmission:!1,hash:"a6b446d19166f17f313008e6c056f3d8",slug:"renewable-energy-technologies-and-applications",bookSignature:"Tolga Taner, Archana Tiwari and Taha Selim Ustun",coverURL:"https://cdn.intechopen.com/books/images_new/9385.jpg",editors:[{id:"197240",title:"Associate Prof.",name:"Tolga",middleName:null,surname:"Taner",slug:"tolga-taner",fullName:"Tolga Taner"}],equalEditorOne:{id:"186791",title:"Dr.",name:"Archana",middleName:null,surname:"Tiwari",slug:"archana-tiwari",fullName:"Archana Tiwari",profilePictureURL:"https://mts.intechopen.com/storage/users/186791/images/system/186791.jpg",biography:"Dr. Archana Tiwari is Associate Professor at Amity University, India. Her research interests include renewable sources of energy from microalgae and further utilizing the residual biomass for the generation of value-added products, bioremediation through microalgae and microbial consortium, antioxidative enzymes and stress, and nutraceuticals from microalgae. She has been working on algal biotechnology for the last two decades. She has published her research in many international journals and has authored many books and chapters with renowned publishing houses. She has also delivered talks as an invited speaker at many national and international conferences. Dr. Tiwari is the recipient of several awards including Researcher of the Year and Distinguished Scientist.",institutionString:"Amity University",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"3",totalChapterViews:"0",totalEditedBooks:"1",institution:{name:"Amity University",institutionURL:null,country:{name:"India"}}},equalEditorTwo:{id:"197609",title:"Prof.",name:"Taha Selim",middleName:null,surname:"Ustun",slug:"taha-selim-ustun",fullName:"Taha Selim Ustun",profilePictureURL:"https://mts.intechopen.com/storage/users/197609/images/system/197609.jpeg",biography:"Dr. Taha Selim Ustun received a Ph.D. in Electrical Engineering from Victoria University, Melbourne, Australia. He is a researcher with the Fukushima Renewable Energy Institute, AIST (FREA), where he leads the Smart Grid Cybersecurity Laboratory. Prior to that, he was a faculty member with the School of Electrical and Computer Engineering, Carnegie Mellon University, Pittsburgh, PA, USA. His current research interests include power systems protection, communication in power networks, distributed generation, microgrids, electric vehicle integration, and cybersecurity in smart grids. He serves on the editorial boards of IEEE Access, IEEE Transactions on Industrial Informatics, Energies, Electronics, Electricity, World Electric Vehicle and Information journals. Dr. Ustun is a member of the IEEE 2004 and 2800, IEC Renewable Energy Management WG 8, and IEC TC 57 WG17. He has been invited to run specialist courses in Africa, India, and China. He has delivered talks for the Qatar Foundation, the World Energy Council, the Waterloo Global Science Initiative, and the European Union Energy Initiative (EUEI). His research has attracted funding from prestigious programs in Japan, Australia, the European Union, and North America.",institutionString:"Fukushima Renewable Energy Institute, AIST (FREA)",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"1",totalChapterViews:"0",totalEditedBooks:"0",institution:{name:"National Institute of Advanced Industrial Science and Technology",institutionURL:null,country:{name:"Japan"}}},equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"8985",title:"Natural Resources Management and Biological Sciences",subtitle:null,isOpenForSubmission:!1,hash:"5c2e219a6c021a40b5a20c041dea88c4",slug:"natural-resources-management-and-biological-sciences",bookSignature:"Edward R. Rhodes and Humood Naser",coverURL:"https://cdn.intechopen.com/books/images_new/8985.jpg",editors:[{id:"280886",title:"Prof.",name:"Edward R",middleName:null,surname:"Rhodes",slug:"edward-r-rhodes",fullName:"Edward R Rhodes"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9027",title:"Human Blood Group Systems and Haemoglobinopathies",subtitle:null,isOpenForSubmission:!1,hash:"d00d8e40b11cfb2547d1122866531c7e",slug:"human-blood-group-systems-and-haemoglobinopathies",bookSignature:"Osaro Erhabor and Anjana Munshi",coverURL:"https://cdn.intechopen.com/books/images_new/9027.jpg",editors:[{id:"35140",title:null,name:"Osaro",middleName:null,surname:"Erhabor",slug:"osaro-erhabor",fullName:"Osaro Erhabor"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"7841",title:"New Insights Into Metabolic Syndrome",subtitle:null,isOpenForSubmission:!1,hash:"ef5accfac9772b9e2c9eff884f085510",slug:"new-insights-into-metabolic-syndrome",bookSignature:"Akikazu Takada",coverURL:"https://cdn.intechopen.com/books/images_new/7841.jpg",editors:[{id:"248459",title:"Dr.",name:"Akikazu",middleName:null,surname:"Takada",slug:"akikazu-takada",fullName:"Akikazu Takada"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"8558",title:"Aerodynamics",subtitle:null,isOpenForSubmission:!1,hash:"db7263fc198dfb539073ba0260a7f1aa",slug:"aerodynamics",bookSignature:"Mofid Gorji-Bandpy and Aly-Mousaad Aly",coverURL:"https://cdn.intechopen.com/books/images_new/8558.jpg",editors:[{id:"35542",title:"Prof.",name:"Mofid",middleName:null,surname:"Gorji-Bandpy",slug:"mofid-gorji-bandpy",fullName:"Mofid Gorji-Bandpy"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9668",title:"Chemistry and Biochemistry of Winemaking, Wine Stabilization and Aging",subtitle:null,isOpenForSubmission:!1,hash:"c5484276a314628acf21ec1bdc3a86b9",slug:"chemistry-and-biochemistry-of-winemaking-wine-stabilization-and-aging",bookSignature:"Fernanda Cosme, Fernando M. Nunes and Luís Filipe-Ribeiro",coverURL:"https://cdn.intechopen.com/books/images_new/9668.jpg",editors:[{id:"186819",title:"Prof.",name:"Fernanda",middleName:null,surname:"Cosme",slug:"fernanda-cosme",fullName:"Fernanda Cosme"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"7847",title:"Medical Toxicology",subtitle:null,isOpenForSubmission:!1,hash:"db9b65bea093de17a0855a1b27046247",slug:"medical-toxicology",bookSignature:"Pınar Erkekoglu and Tomohisa Ogawa",coverURL:"https://cdn.intechopen.com/books/images_new/7847.jpg",editors:[{id:"109978",title:"Prof.",name:"Pınar",middleName:null,surname:"Erkekoglu",slug:"pinar-erkekoglu",fullName:"Pınar Erkekoglu"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"8620",title:"Mining Techniques",subtitle:"Past, Present and Future",isOpenForSubmission:!1,hash:"b65658f81d14e9e57e49377869d3a575",slug:"mining-techniques-past-present-and-future",bookSignature:"Abhay Soni",coverURL:"https://cdn.intechopen.com/books/images_new/8620.jpg",editors:[{id:"271093",title:"Dr.",name:"Abhay",middleName:null,surname:"Soni",slug:"abhay-soni",fullName:"Abhay Soni"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9660",title:"Inland Waters",subtitle:"Dynamics and Ecology",isOpenForSubmission:!1,hash:"975c26819ceb11a926793bc2adc62bd6",slug:"inland-waters-dynamics-and-ecology",bookSignature:"Adam Devlin, Jiayi Pan and Mohammad Manjur Shah",coverURL:"https://cdn.intechopen.com/books/images_new/9660.jpg",editors:[{id:"280757",title:"Dr.",name:"Adam",middleName:"Thomas",surname:"Devlin",slug:"adam-devlin",fullName:"Adam Devlin"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9122",title:"Cosmetic Surgery",subtitle:null,isOpenForSubmission:!1,hash:"207026ca4a4125e17038e770d00ee152",slug:"cosmetic-surgery",bookSignature:"Yueh-Bih Tang",coverURL:"https://cdn.intechopen.com/books/images_new/9122.jpg",editors:[{id:"202122",title:"Prof.",name:"Yueh-Bih",middleName:null,surname:"Tang",slug:"yueh-bih-tang",fullName:"Yueh-Bih Tang"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}}],latestBooks:[{type:"book",id:"9550",title:"Entrepreneurship",subtitle:"Contemporary Issues",isOpenForSubmission:!1,hash:"9b4ac1ee5b743abf6f88495452b1e5e7",slug:"entrepreneurship-contemporary-issues",bookSignature:"Mladen Turuk",coverURL:"https://cdn.intechopen.com/books/images_new/9550.jpg",editedByType:"Edited by",editors:[{id:"319755",title:"Prof.",name:"Mladen",middleName:null,surname:"Turuk",slug:"mladen-turuk",fullName:"Mladen Turuk"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10065",title:"Wavelet Theory",subtitle:null,isOpenForSubmission:!1,hash:"d8868e332169597ba2182d9b004d60de",slug:"wavelet-theory",bookSignature:"Somayeh Mohammady",coverURL:"https://cdn.intechopen.com/books/images_new/10065.jpg",editedByType:"Edited by",editors:[{id:"109280",title:"Dr.",name:"Somayeh",middleName:null,surname:"Mohammady",slug:"somayeh-mohammady",fullName:"Somayeh Mohammady"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9313",title:"Clay Science and Technology",subtitle:null,isOpenForSubmission:!1,hash:"6fa7e70396ff10620e032bb6cfa6fb72",slug:"clay-science-and-technology",bookSignature:"Gustavo Morari Do Nascimento",coverURL:"https://cdn.intechopen.com/books/images_new/9313.jpg",editedByType:"Edited by",editors:[{id:"7153",title:"Prof.",name:"Gustavo",middleName:null,surname:"Morari Do Nascimento",slug:"gustavo-morari-do-nascimento",fullName:"Gustavo Morari Do Nascimento"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9888",title:"Nuclear Power Plants",subtitle:"The Processes from the Cradle to the Grave",isOpenForSubmission:!1,hash:"c2c8773e586f62155ab8221ebb72a849",slug:"nuclear-power-plants-the-processes-from-the-cradle-to-the-grave",bookSignature:"Nasser Awwad",coverURL:"https://cdn.intechopen.com/books/images_new/9888.jpg",editedByType:"Edited by",editors:[{id:"145209",title:"Prof.",name:"Nasser",middleName:"S",surname:"Awwad",slug:"nasser-awwad",fullName:"Nasser Awwad"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"8098",title:"Resources of Water",subtitle:null,isOpenForSubmission:!1,hash:"d251652996624d932ef7b8ed62cf7cfc",slug:"resources-of-water",bookSignature:"Prathna Thanjavur Chandrasekaran, Muhammad Salik Javaid, Aftab Sadiq",coverURL:"https://cdn.intechopen.com/books/images_new/8098.jpg",editedByType:"Edited by",editors:[{id:"167917",title:"Dr.",name:"Prathna",middleName:null,surname:"Thanjavur Chandrasekaran",slug:"prathna-thanjavur-chandrasekaran",fullName:"Prathna Thanjavur Chandrasekaran"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9644",title:"Glaciers and the Polar Environment",subtitle:null,isOpenForSubmission:!1,hash:"e8cfdc161794e3753ced54e6ff30873b",slug:"glaciers-and-the-polar-environment",bookSignature:"Masaki Kanao, Danilo Godone and Niccolò Dematteis",coverURL:"https://cdn.intechopen.com/books/images_new/9644.jpg",editedByType:"Edited by",editors:[{id:"51959",title:"Dr.",name:"Masaki",middleName:null,surname:"Kanao",slug:"masaki-kanao",fullName:"Masaki Kanao"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10432",title:"Casting Processes and Modelling of Metallic Materials",subtitle:null,isOpenForSubmission:!1,hash:"2c5c9df938666bf5d1797727db203a6d",slug:"casting-processes-and-modelling-of-metallic-materials",bookSignature:"Zakaria Abdallah and Nada Aldoumani",coverURL:"https://cdn.intechopen.com/books/images_new/10432.jpg",editedByType:"Edited by",editors:[{id:"201670",title:"Dr.",name:"Zak",middleName:null,surname:"Abdallah",slug:"zak-abdallah",fullName:"Zak Abdallah"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9671",title:"Macrophages",subtitle:null,isOpenForSubmission:!1,hash:"03b00fdc5f24b71d1ecdfd75076bfde6",slug:"macrophages",bookSignature:"Hridayesh Prakash",coverURL:"https://cdn.intechopen.com/books/images_new/9671.jpg",editedByType:"Edited by",editors:[{id:"287184",title:"Dr.",name:"Hridayesh",middleName:null,surname:"Prakash",slug:"hridayesh-prakash",fullName:"Hridayesh Prakash"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"8415",title:"Extremophilic Microbes and Metabolites",subtitle:"Diversity, Bioprospecting and Biotechnological Applications",isOpenForSubmission:!1,hash:"93e0321bc93b89ff73730157738f8f97",slug:"extremophilic-microbes-and-metabolites-diversity-bioprospecting-and-biotechnological-applications",bookSignature:"Afef Najjari, Ameur Cherif, Haïtham Sghaier and Hadda Imene Ouzari",coverURL:"https://cdn.intechopen.com/books/images_new/8415.jpg",editedByType:"Edited by",editors:[{id:"196823",title:"Dr.",name:"Afef",middleName:null,surname:"Najjari",slug:"afef-najjari",fullName:"Afef Najjari"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9731",title:"Oxidoreductase",subtitle:null,isOpenForSubmission:!1,hash:"852e6f862c85fc3adecdbaf822e64e6e",slug:"oxidoreductase",bookSignature:"Mahmoud Ahmed Mansour",coverURL:"https://cdn.intechopen.com/books/images_new/9731.jpg",editedByType:"Edited by",editors:[{id:"224662",title:"Prof.",name:"Mahmoud Ahmed",middleName:null,surname:"Mansour",slug:"mahmoud-ahmed-mansour",fullName:"Mahmoud Ahmed Mansour"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}]},subject:{topic:{id:"913",title:"Proteomics",slug:"structural-biology-proteomics",parent:{title:"Structural Biology",slug:"structural-biology"},numberOfBooks:7,numberOfAuthorsAndEditors:174,numberOfWosCitations:48,numberOfCrossrefCitations:28,numberOfDimensionsCitations:71,videoUrl:null,fallbackUrl:null,description:null},booksByTopicFilter:{topicSlug:"structural-biology-proteomics",sort:"-publishedDate",limit:12,offset:0},booksByTopicCollection:[{type:"book",id:"9742",title:"Ubiquitin",subtitle:"Proteasome Pathway",isOpenForSubmission:!1,hash:"af6880d3a5571da1377ac8f6373b9e82",slug:"ubiquitin-proteasome-pathway",bookSignature:"Xianquan Zhan",coverURL:"https://cdn.intechopen.com/books/images_new/9742.jpg",editedByType:"Edited by",editors:[{id:"223233",title:"Prof.",name:"Xianquan",middleName:null,surname:"Zhan",slug:"xianquan-zhan",fullName:"Xianquan Zhan"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9352",title:"Proteoforms",subtitle:"Concept and Applications in Medical Sciences",isOpenForSubmission:!1,hash:"0f0288da2d32c0c0fcda6be0d4d45d67",slug:"proteoforms-concept-and-applications-in-medical-sciences",bookSignature:"Xianquan Zhan",coverURL:"https://cdn.intechopen.com/books/images_new/9352.jpg",editedByType:"Edited by",editors:[{id:"223233",title:"Prof.",name:"Xianquan",middleName:null,surname:"Zhan",slug:"xianquan-zhan",fullName:"Xianquan Zhan"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"8301",title:"Ubiquitin Proteasome System",subtitle:"Current Insights into Mechanism Cellular Regulation and Disease",isOpenForSubmission:!1,hash:"ec9eada73dbddb8b41315a3b089302b4",slug:"ubiquitin-proteasome-system-current-insights-into-mechanism-cellular-regulation-and-disease",bookSignature:"Matthew Summers",coverURL:"https://cdn.intechopen.com/books/images_new/8301.jpg",editedByType:"Edited by",editors:[{id:"204371",title:"Associate Prof.",name:"Matthew",middleName:null,surname:"Summers",slug:"matthew-summers",fullName:"Matthew Summers"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"5989",title:"Ubiquitination Governing DNA Repair",subtitle:"Implications in Health and Disease",isOpenForSubmission:!1,hash:"d9892e3c8d2c928119619d7425c9e371",slug:"ubiquitination-governing-dna-repair-implications-in-health-and-disease",bookSignature:"Effrossyni Boutou and Horst-Werner Stürzbecher",coverURL:"https://cdn.intechopen.com/books/images_new/5989.jpg",editedByType:"Edited by",editors:[{id:"58579",title:"Dr.",name:"Effrossyni",middleName:null,surname:"Boutou",slug:"effrossyni-boutou",fullName:"Effrossyni Boutou"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"6649",title:"Peripheral Membrane Proteins",subtitle:null,isOpenForSubmission:!1,hash:"dd98f01959b3ba6cc9483c03e75b9e0a",slug:"peripheral-membrane-proteins",bookSignature:"Shihori Tanabe",coverURL:"https://cdn.intechopen.com/books/images_new/6649.jpg",editedByType:"Edited by",editors:[{id:"48635",title:"Dr.",name:"Shihori",middleName:null,surname:"Tanabe",slug:"shihori-tanabe",fullName:"Shihori Tanabe"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"6635",title:"Protein-Protein Interaction Assays",subtitle:null,isOpenForSubmission:!1,hash:"1bed553d74f0565c89758a7159647634",slug:"protein-protein-interaction-assays",bookSignature:"Mahmood-ur-Rahman Ansari",coverURL:"https://cdn.intechopen.com/books/images_new/6635.jpg",editedByType:"Edited by",editors:[{id:"185476",title:"Dr.",name:"Mahmood-Ur-",middleName:null,surname:"Rahman Ansari",slug:"mahmood-ur-rahman-ansari",fullName:"Mahmood-Ur- Rahman Ansari"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"780",title:"Proteomics",subtitle:"Human Diseases and Protein Functions",isOpenForSubmission:!1,hash:"a90c4e5b369d27036134a3c66ce1cb26",slug:"proteomics-human-diseases-and-protein-functions",bookSignature:"Tsz-Kwong Man and Ricardo J. Flores",coverURL:"https://cdn.intechopen.com/books/images_new/780.jpg",editedByType:"Edited by",editors:[{id:"35047",title:"Prof.",name:"Tsz Kwong",middleName:null,surname:"Man",slug:"tsz-kwong-man",fullName:"Tsz Kwong Man"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}],booksByTopicTotal:7,mostCitedChapters:[{id:"28196",doi:"10.5772/31776",title:"Exploring the Role of Biomarkers for the Diagnosis and Management of Traumatic Brain Injury Patients",slug:"exploring-the-role-of-biomarkers-for-the-diagnosis-and-management-of-traumatic-brain-injury-patients",totalDownloads:2470,totalCrossrefCites:5,totalDimensionsCites:18,book:{slug:"proteomics-human-diseases-and-protein-functions",title:"Proteomics",fullTitle:"Proteomics - Human Diseases and Protein Functions"},signatures:"Linda Papa",authors:[{id:"88648",title:"Dr.",name:"Linda",middleName:null,surname:"Papa",slug:"linda-papa",fullName:"Linda Papa"}]},{id:"28199",doi:"10.5772/31082",title:"F0F1 ATP Synthase: A Fascinating Challenge for Proteomics",slug:"f0f1-atp-synthase-a-fascinating-challenge-for-proteomics",totalDownloads:4979,totalCrossrefCites:2,totalDimensionsCites:7,book:{slug:"proteomics-human-diseases-and-protein-functions",title:"Proteomics",fullTitle:"Proteomics - Human Diseases and Protein Functions"},signatures:"Federica Dabbeni-Sala, Amit Kumar Rai and Giovanna Lippe",authors:[{id:"85523",title:"Prof.",name:"Giovanna",middleName:null,surname:"Lippe",slug:"giovanna-lippe",fullName:"Giovanna Lippe"},{id:"149272",title:"Dr.",name:"Federica",middleName:null,surname:"Dabbeni-Sala",slug:"federica-dabbeni-sala",fullName:"Federica Dabbeni-Sala"},{id:"149273",title:"Dr.",name:"Amit",middleName:null,surname:"Kumar Rai",slug:"amit-kumar-rai",fullName:"Amit Kumar Rai"}]},{id:"66145",doi:"10.5772/intechopen.83426",title:"New Insights into the Mechanisms Underlying NEDD8 Structural and Functional Specificities",slug:"new-insights-into-the-mechanisms-underlying-nedd8-structural-and-functional-specificities",totalDownloads:452,totalCrossrefCites:2,totalDimensionsCites:4,book:{slug:"ubiquitin-proteasome-system-current-insights-into-mechanism-cellular-regulation-and-disease",title:"Ubiquitin Proteasome System",fullTitle:"Ubiquitin Proteasome System - Current Insights into Mechanism Cellular Regulation and Disease"},signatures:"Elena Santonico",authors:[{id:"271923",title:"Dr.",name:"Elena",middleName:null,surname:"Santonico",slug:"elena-santonico",fullName:"Elena Santonico"}]}],mostDownloadedChaptersLast30Days:[{id:"61472",title:"Introductory Chapter: Protein-Protein Interactions and Assays",slug:"introductory-chapter-protein-protein-interactions-and-assays",totalDownloads:1227,totalCrossrefCites:1,totalDimensionsCites:2,book:{slug:"protein-protein-interaction-assays",title:"Protein-Protein Interaction Assays",fullTitle:"Protein-Protein Interaction Assays"},signatures:"Munazza Ijaz, Mahmood-ur-Rahman Ansari and Muhammad Iqbal",authors:[{id:"185476",title:"Dr.",name:"Mahmood-Ur-",middleName:null,surname:"Rahman Ansari",slug:"mahmood-ur-rahman-ansari",fullName:"Mahmood-Ur- Rahman Ansari"},{id:"252871",title:"Ms.",name:"Munazza",middleName:null,surname:"Ijaz",slug:"munazza-ijaz",fullName:"Munazza Ijaz"},{id:"252872",title:"Dr.",name:"Muhammad",middleName:null,surname:"Iqbal",slug:"muhammad-iqbal",fullName:"Muhammad Iqbal"}]},{id:"61295",title:"Protein Interactions and Nanomaterials: A Key Role of the Protein Corona in Nanobiocompatibility",slug:"protein-interactions-and-nanomaterials-a-key-role-of-the-protein-corona-in-nanobiocompatibility",totalDownloads:689,totalCrossrefCites:2,totalDimensionsCites:2,book:{slug:"protein-protein-interaction-assays",title:"Protein-Protein Interaction Assays",fullTitle:"Protein-Protein Interaction Assays"},signatures:"Micaelo Ânia , Rodriguez Emilio , Millan Angel , Gongora Rafael and\nFuentes Manuel",authors:[{id:"173804",title:"Dr.",name:"Manuel",middleName:null,surname:"Fuentes",slug:"manuel-fuentes",fullName:"Manuel Fuentes"}]},{id:"28199",title:"F0F1 ATP Synthase: A Fascinating Challenge for Proteomics",slug:"f0f1-atp-synthase-a-fascinating-challenge-for-proteomics",totalDownloads:4983,totalCrossrefCites:2,totalDimensionsCites:7,book:{slug:"proteomics-human-diseases-and-protein-functions",title:"Proteomics",fullTitle:"Proteomics - Human Diseases and Protein Functions"},signatures:"Federica Dabbeni-Sala, Amit Kumar Rai and Giovanna Lippe",authors:[{id:"85523",title:"Prof.",name:"Giovanna",middleName:null,surname:"Lippe",slug:"giovanna-lippe",fullName:"Giovanna Lippe"},{id:"149272",title:"Dr.",name:"Federica",middleName:null,surname:"Dabbeni-Sala",slug:"federica-dabbeni-sala",fullName:"Federica Dabbeni-Sala"},{id:"149273",title:"Dr.",name:"Amit",middleName:null,surname:"Kumar Rai",slug:"amit-kumar-rai",fullName:"Amit Kumar Rai"}]},{id:"28201",title:"Identification of the Novel Plasminogen Receptor, Plg-RKT",slug:"identification-of-the-novel-plasminogen-receptor-plg-rkt",totalDownloads:1984,totalCrossrefCites:1,totalDimensionsCites:2,book:{slug:"proteomics-human-diseases-and-protein-functions",title:"Proteomics",fullTitle:"Proteomics - Human Diseases and Protein Functions"},signatures:"Lindsey A. Miles, Nicholas M. Andronicos, Emily I. Chen, Nagyung Baik, Hongdong Bai, Caitlin M. Parmer, Shahrzad Lighvani, Samir Nangia, William B. Kiosses, Mark P. Kamps, John R. Yates III and Robert J. Parmer",authors:[{id:"85634",title:"Dr.",name:"Lindsey A.",middleName:null,surname:"Miles",slug:"lindsey-a.-miles",fullName:"Lindsey A. Miles"},{id:"85772",title:"Dr.",name:"Nicholas M.",middleName:null,surname:"Andronicos",slug:"nicholas-m.-andronicos",fullName:"Nicholas M. Andronicos"},{id:"85773",title:"Dr.",name:"Emily I.",middleName:null,surname:"Chen",slug:"emily-i.-chen",fullName:"Emily I. Chen"},{id:"85775",title:"MSc.",name:"Nagyung",middleName:null,surname:"Baik",slug:"nagyung-baik",fullName:"Nagyung Baik"},{id:"85776",title:"Dr.",name:"Hongdong",middleName:null,surname:"Bai",slug:"hongdong-bai",fullName:"Hongdong Bai"},{id:"85777",title:"Ms.",name:"Caitlin M.",middleName:null,surname:"Parmer",slug:"caitlin-m.-parmer",fullName:"Caitlin M. Parmer"},{id:"85778",title:"Dr.",name:"William B.",middleName:null,surname:"Kiosses",slug:"william-b.-kiosses",fullName:"William B. Kiosses"},{id:"85780",title:"Dr.",name:"John R.",middleName:null,surname:"Yates, III",slug:"john-r.-yates-iii",fullName:"John R. Yates, III"},{id:"85781",title:"Dr.",name:"Robert J.",middleName:null,surname:"Parmer",slug:"robert-j.-parmer",fullName:"Robert J. Parmer"},{id:"123594",title:"Dr.",name:"Samir",middleName:null,surname:"Nangia",slug:"samir-nangia",fullName:"Samir Nangia"},{id:"123595",title:"Dr.",name:"Shahrzad",middleName:null,surname:"Lighvani",slug:"shahrzad-lighvani",fullName:"Shahrzad Lighvani"}]},{id:"28195",title:"Circadian Proteomics and Its Unique Advantage for Discovery of Biomarkers of Heart Disease",slug:"circadian-proteomics-and-its-unique-advantage-for-discovery-of-biomarkers-of-heart-disease",totalDownloads:2046,totalCrossrefCites:0,totalDimensionsCites:4,book:{slug:"proteomics-human-diseases-and-protein-functions",title:"Proteomics",fullTitle:"Proteomics - Human Diseases and Protein Functions"},signatures:"Peter S. Podobed, Gordon M. Kirby and Tami A. Martino",authors:[{id:"78041",title:"Prof.",name:"Tami A.",middleName:null,surname:"Martino",slug:"tami-a.-martino",fullName:"Tami A. Martino"},{id:"89335",title:"Dr.",name:"Peter",middleName:"S",surname:"Podobed",slug:"peter-podobed",fullName:"Peter Podobed"},{id:"123931",title:"Prof.",name:"Gordon M.",middleName:null,surname:"Kirby",slug:"gordon-m.-kirby",fullName:"Gordon M. Kirby"}]},{id:"69506",title:"Preparing Proteoforms of Therapeutic Proteins for Top-Down Mass Spectrometry",slug:"preparing-proteoforms-of-therapeutic-proteins-for-top-down-mass-spectrometry",totalDownloads:302,totalCrossrefCites:0,totalDimensionsCites:0,book:{slug:"proteoforms-concept-and-applications-in-medical-sciences",title:"Proteoforms",fullTitle:"Proteoforms - Concept and Applications in Medical Sciences"},signatures:"Siti Nurul Hidayah, Manasi Gaikwad, Laura Heikaus and Hartmut Schlüter",authors:[{id:"307264",title:"Prof.",name:"Hartmut",middleName:null,surname:"Schlüter",slug:"hartmut-schluter",fullName:"Hartmut Schlüter"},{id:"310153",title:"Ms.",name:"Siti Nurul",middleName:null,surname:"Hidayah",slug:"siti-nurul-hidayah",fullName:"Siti Nurul Hidayah"},{id:"310154",title:"Ms.",name:"Manasi",middleName:null,surname:"Gaikwad",slug:"manasi-gaikwad",fullName:"Manasi Gaikwad"},{id:"310155",title:"Ms.",name:"Laura",middleName:null,surname:"Heikaus",slug:"laura-heikaus",fullName:"Laura Heikaus"}]},{id:"60064",title:"Rapid Endosomal Recycling",slug:"rapid-endosomal-recycling",totalDownloads:682,totalCrossrefCites:1,totalDimensionsCites:1,book:{slug:"peripheral-membrane-proteins",title:"Peripheral Membrane Proteins",fullTitle:"Peripheral Membrane Proteins"},signatures:"Hana Mahmutefendić, Gordana Blagojević Zagorac, Senka Maćešić\nand Pero Lučin",authors:[{id:"152008",title:"Prof.",name:"Pero",middleName:null,surname:"Lučin",slug:"pero-lucin",fullName:"Pero Lučin"},{id:"245873",title:"Prof.",name:"Hana",middleName:null,surname:"Mahmutefendić",slug:"hana-mahmutefendic",fullName:"Hana Mahmutefendić"},{id:"245875",title:"Prof.",name:"Gordana",middleName:null,surname:"Blagojević Zagorac",slug:"gordana-blagojevic-zagorac",fullName:"Gordana Blagojević Zagorac"},{id:"245876",title:"Prof.",name:"Senka",middleName:null,surname:"Maćešić",slug:"senka-macesic",fullName:"Senka Maćešić"}]},{id:"57018",title:"Ubiquitination and DNA Repair in Multiple Myeloma",slug:"ubiquitination-and-dna-repair-in-multiple-myeloma",totalDownloads:516,totalCrossrefCites:0,totalDimensionsCites:0,book:{slug:"ubiquitination-governing-dna-repair-implications-in-health-and-disease",title:"Ubiquitination Governing DNA Repair",fullTitle:"Ubiquitination Governing DNA Repair - Implications in Health and Disease"},signatures:"Lisa J. Crawford and Alexandra E. Irvine",authors:[{id:"88220",title:"Dr.",name:"Alexandra",middleName:null,surname:"Irvine",slug:"alexandra-irvine",fullName:"Alexandra Irvine"},{id:"202927",title:"Dr.",name:"Lisa",middleName:null,surname:"Crawford",slug:"lisa-crawford",fullName:"Lisa Crawford"}]},{id:"58366",title:"Ubiquitylation and SUMOylation: An Orchestrated Regulation During DNA Damage Repair",slug:"ubiquitylation-and-sumoylation-an-orchestrated-regulation-during-dna-damage-repair",totalDownloads:504,totalCrossrefCites:0,totalDimensionsCites:0,book:{slug:"ubiquitination-governing-dna-repair-implications-in-health-and-disease",title:"Ubiquitination Governing DNA Repair",fullTitle:"Ubiquitination Governing DNA Repair - Implications in Health and Disease"},signatures:"Sara Espinoza-Corona, Ma Luisa Bazán-Tejeda, Ulises Omar García-\nLepe and Rosa Ma Bermúdez-Cruz",authors:[{id:"205238",title:"Dr.",name:"Rosa",middleName:null,surname:"Bermudez",slug:"rosa-bermudez",fullName:"Rosa Bermudez"},{id:"207883",title:"MSc.",name:"Sara",middleName:null,surname:"Espinoza-Corona",slug:"sara-espinoza-corona",fullName:"Sara Espinoza-Corona"},{id:"207884",title:"Dr.",name:"Maria Luisa",middleName:null,surname:"Bazan-Tejeda",slug:"maria-luisa-bazan-tejeda",fullName:"Maria Luisa Bazan-Tejeda"},{id:"207885",title:"BSc.",name:"Ulises Omar",middleName:null,surname:"Garcia-Lepe",slug:"ulises-omar-garcia-lepe",fullName:"Ulises Omar Garcia-Lepe"}]},{id:"65025",title:"E3 Ubiquitin Ligases in Cancer and Their Pharmacological Targeting",slug:"e3-ubiquitin-ligases-in-cancer-and-their-pharmacological-targeting",totalDownloads:1033,totalCrossrefCites:0,totalDimensionsCites:2,book:{slug:"ubiquitin-proteasome-system-current-insights-into-mechanism-cellular-regulation-and-disease",title:"Ubiquitin Proteasome System",fullTitle:"Ubiquitin Proteasome System - Current Insights into Mechanism Cellular Regulation and Disease"},signatures:"Joseph Y. Ong and Jorge Z. Torres",authors:[{id:"186645",title:"Dr.",name:"Jorge",middleName:null,surname:"Torres",slug:"jorge-torres",fullName:"Jorge Torres"},{id:"264944",title:"Mr.",name:"Joseph",middleName:null,surname:"Ong",slug:"joseph-ong",fullName:"Joseph Ong"}]}],onlineFirstChaptersFilter:{topicSlug:"structural-biology-proteomics",limit:3,offset:0},onlineFirstChaptersCollection:[{id:"75283",title:"Homology Modeling of Tubulin Isotypes to Investigate MT-Tau Interactions",slug:"homology-modeling-of-tubulin-isotypes-to-investigate-mt-tau-interactions",totalDownloads:8,totalDimensionsCites:0,doi:"10.5772/intechopen.95792",book:{title:"Homology Molecular Modeling - Perspectives and Applications"},signatures:"Vishwambhar Vishnu Bhandare"},{id:"73828",title:"Importance of Homology Modeling for Predicting the Structures of GPCRs",slug:"importance-of-homology-modeling-for-predicting-the-structures-of-gpcrs",totalDownloads:96,totalDimensionsCites:0,doi:"10.5772/intechopen.94402",book:{title:"Homology Molecular Modeling - Perspectives and Applications"},signatures:"Ananthasri Sailapathi, Seshan Gunalan, Kanagasabai Somarathinam, Gugan Kothandan and Diwakar Kumar"},{id:"74105",title:"Energy Minimization",slug:"energy-minimization",totalDownloads:100,totalDimensionsCites:0,doi:"10.5772/intechopen.94809",book:{title:"Homology Molecular Modeling - Perspectives and Applications"},signatures:"Budhayash Gautam"}],onlineFirstChaptersTotal:6},preDownload:{success:null,errors:{}},aboutIntechopen:{},privacyPolicy:{},peerReviewing:{},howOpenAccessPublishingWithIntechopenWorks:{},sponsorshipBooks:{sponsorshipBooks:[{type:"book",id:"10176",title:"Microgrids and Local Energy Systems",subtitle:null,isOpenForSubmission:!0,hash:"c32b4a5351a88f263074b0d0ca813a9c",slug:null,bookSignature:"Prof. Nick Jenkins",coverURL:"https://cdn.intechopen.com/books/images_new/10176.jpg",editedByType:null,editors:[{id:"55219",title:"Prof.",name:"Nick",middleName:null,surname:"Jenkins",slug:"nick-jenkins",fullName:"Nick Jenkins"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}}],offset:8,limit:8,total:1},route:{name:"profile.detail",path:"/profiles/170449/taworn-thunjai",hash:"",query:{},params:{id:"170449",slug:"taworn-thunjai"},fullPath:"/profiles/170449/taworn-thunjai",meta:{},from:{name:null,path:"/",hash:"",query:{},params:{},fullPath:"/",meta:{}}}},function(){var e;(e=document.currentScript||document.scripts[document.scripts.length-1]).parentNode.removeChild(e)}()